Sylvester Comprehensive Cancer Center

E-mail a Friend

Breelyn A. Wilky, M.D.

General Information

Breelyn A. Wilky, M.D.

Contact

  • Fax: 305-243-8796

Languages

  • English

Certifications

  • American Board of Internal Medicine
  • American Board of Internal Med-Medical Oncology

CV

Specialties

  • Internal Medicine
  • Hematology/Oncology - Internal Medicine

Roles

  • Assistant Professor, Sarcoma Program

Clinical Interests

Bone and Soft Tissue Cancer (Sarcomas)

GIST

Desmoid Tumors

Pigmented Villonodular Synovitis (PVNS)

Awards

Alpha Omega Alpha
Desmoid Tumor Research Foundation Research Grant
American Cancer Society Institutional Research Grant
Sylvester Comprehensive Cancer Center Clinical Trial Acceleration Grant
Conquer Cancer Foundation/ASCO Young Investigator Award
Alpha Omega Alpha Postgraduate Award
Connie Caplan Medical Oncology Fellowship
Gold Humanism Honor Society

Education

2009-2013 Fellowship
Johns Hopkins University
2006-2009 Internship and Residency
Johns Hopkins Hospital
2006 M.D. with Distinction in Research
University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School
2001 BS
Bates College

Publications

Biography

I am a medical oncologist specializing in benign and malignant disorders of bone and soft tissue, including sarcomas.  In addition to clinical care of patients suffering from these rare cancers, I am a clinical and translational researcher, working to develop new therapies apart from traditional chemotherapy approaches.  I am particularly interested in the role of immunotherapy for sarcomas, and am currently leading three clinical trials at Sylvester Comprehensive Cancer Center investigating immune checkpoint inhibitors and patient-derived vaccines.  In addition to studying whether these treatment approaches can help patients with sarcoma, I also work with laboratory investigators to study the immune cells from patients treated on these trials, to understand how we can help the immune system fight cancer more effectively.  

In addition to my research for sarcoma patients, I am an active member of our Phase I Site Disease Group and also participate in Sylvester's Personalized Medicine Initiatives, which aim to match patients to the best molecularly targeted treatments available based on the patient's own genetic sequencing results from tumor tissue.  

Along with my exceptional colleagues in surgical oncology, radiation oncology, pediatric oncology, pathology, musculoskeletal and interventional radiology, and supportive care, our sarcoma team aims to provide each patient with the best, customized treatment plan to ensure everyone has the highest chances of conquering cancer, whether through standard treatments or the latest cutting-edge clinical trials.  

E-mail a Friend